The company is trading at less than 10% of BioVids projected value 7months from now with a BLA Application filed. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. In the evenings, Alan teaches economics at a local community college.  The company is the largest franchisee of IHOP with 300 restaurants and 4 partnerships. Jul 15, 2020 5:53pm EDT. CytoDyn Inc (CYDY) announced that Michael A. Klump joined the Board of Directors at CytoDyn. VANCOUVER, Washington, July 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it recently filed a comprehensive listing application package with The Nasdaq Stock Market to request an uplisting of …   Dr. Pestell has published over 600 publications and is most commonly cited for his work in prostate cancer.  The new and improved pipeline means the company is almost 30 times as large but the stock has not recognized the potential of the cancer indications. HGEN uplisted on September 4th, 2020.  In February this year it rolled out a new 3 drug combination called Biktarvy.  Merck (MRK) has a small presence but there is a long history of MRK in HIV and if there is a bidding war they are sure to join in. At this time, there are minimal treatment options for COVID-19. How did you like this article?  Although the merger with ProstaGene hasn’t been finalized it seems clear that they are moving ahead and the market has not come to grips with the true potential of the deal which should more closely resemble a platform technology like Seattle Genetics (SGEN). "Following" : "Follow"}} … Re: (My Fav Excerpts, Part 4 )- Insider Financial: RISE of COVID-19 Therapeutics CytoDyn (GREAT FIND Jakeflies!)   Dr. Pestell has published over 600 publications and is most commonly cited for his work in prostate cancer.  Each one of these companies has a vested stake and billions of dollars invested in the current standard of care called Highly Active Antiretroviral Treatment (HAART). They could be saying hello NASDAQ, and hello EUA in the course of the next couple of weeks.  At the closing of the transaction Dr. Pestell is expected to join CYDY’s Board of Directors.  In his work he use two somewhat toxic CCR5 antagonists, which “dramatically enhanced the cell killing mediated by DNA damaging chemotherapeutic agents.”      Â, The addition of a tycoon investor and a world renown cancer expert to the CYDY board indicates activity as a minimum.  Before starting his own company he was a researcher at the Jefferson College of Life Sciences where he worked on the molecular mechanism and gene therapy of breast and prostate cancer.   A video titled, Cancer Metastasis Promotion by CCR5 Receptor, is a must see.  In a, Deborah Waterhouse, head of GSK’s ViiV Healthcare indicated they “aim to overtake Gilead as market leader in the $26 Billion-a-year HIV market by the mid 2020’s, assuming the gamble on two-drug combinations pans out.”  The gamble lies in the fact that the virus might have an easier chance of developing a drug resistance to two drugs versus three but there was no evidence of that in the 48 week trial. Nasdaq Listing application- provide a detailed description of all inquiries, investigations, lawsuits, litigation, arbitration, hearings, or any other legal or administrative proceedings CytoDyn surprise up lists to AMEX. About Coronavirus Disease 2019CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country. Email Print Friendly Share. CytoDyn (OTCQB:CYDY +4.5%) has filed a comprehensive listing application package with The Nasdaq Stock Market to request an uplisting of its common stock. Yesterday CytoDyn Inc. (OTCMKTS) delivered a gripping investor update after hours clearly projecting a bright path forward that included an uplisting to a major exchange without immediate term dilution. PRO 140 is an entry inhibitor for the HIV virus but the applications extend far beyond HIV. Figure 4 above can be very confusing but the common theme is that CCL5 is doing a lot of things to stimulate the growth and metastasis of breast cancer.  In a recent article Deborah Waterhouse, head of GSK’s ViiV Healthcare indicated they “aim to overtake Gilead as market leader in the $26 Billion-a-year HIV market by the mid 2020’s, assuming the gamble on two-drug combinations pans out.”  The gamble lies in the fact that the virus might have an easier chance of developing a drug resistance to two drugs versus three but there was no evidence of that in the 48 week trial. Same result as A.  Behind them is Johnson and Johnson (JNJ) which just made news last month when it announce, of Symtuza. The next potential suitor is Glaxo SmithKline (GSK) which has 2, highest selling HIV drugs (Triumeq & Tivicay) and a new two drug combination of dolutegravir and lamivudine in the works.  The implications for stem cell implants are just scratching the surface. When criteria path is met (stock holder's e - #6029358 CYDY CytoDyn Inc: Cytodyn filed application for uplist to NASDAQ in July.  The Mesenchymal Stromal Cells (MSC) responsible for increasing CCL5 levels would also be taken out of the equation leaving the CD8+ T-cell not depicted in the drawing to be allowed to migrate into the tumor microenvironment and kill the cancer cells. They are enrolling in about 13 clinical trials and it’s expected that CYDY will enroll in 3 cancer clinical trials plus the 2 HIV trials and the GvHD. Physicians reluctant to change might be slow to uptake the new combination pill for the fear of resistance justified or not. TalkMarkets Newswire is a premier service which disseminates and distributes critical news, press releases and information about a variety of companies.  The whole industry is only one drug approval away from billions in research going down the drain. A once a week injectable for 3 months in hope of eliminating GvHD would be an absolute game changer for this group of people as PRO140 doesn’t have the side effects of suppressing the immune system. Before you start, gather some basic company information. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. With the recent acquisition of ProstaGene almost complete, world renowned scientist Dr Richard Pestell stepped in as the Chief Medical Officer (CMO) to oversee a massive pipeline of oncology indications that are likely to follow as metastasis is the concern in nearly every cancer indication. His career progressed from that point to his current position as senior trader on an institutional trading desk.  At the closing of the transaction Dr. Pestell is, CYDY’s Board of Directors. This is the backbone of the platform technology. PRO 140 has successfully completed one pivotal phase 3 trial for combination therapy and another Phase 3 investigative trial in Monotherapy has completed enrollment and is in the process of completing their rolling Biologics License Application (BLA) for their first approval for combination therapy in HIV. The next potential suitor is Glaxo SmithKline (GSK) which has 2nd and 4th highest selling HIV drugs (Triumeq & Tivicay) and a new two drug combination of dolutegravir and lamivudine in the works.      Â, US Investors Can Now Trade In Virtual Currency Via Bitcoin Exchange Traded Notes (ETN), Crypto Facilities Announces Support For Bitcoin Cash Futures, Consumer Technology Boom Continues: Audio Stocks (DBL, HRAL, SONO), Crypto Stocks Shine as Risk Capital Returns (RIOT, AXXA, CAN), Investors Remain Focused on the Crypto Space (HVBTF, MINE, MARA).  SGEN has an antibody-drug conjugate (ADC) that they can attached a cytotoxic agent that is delivered to the target antigen.  The timing of his appointment seems to be calculated as the company plans on courting suitors for licensing or acquisition deals with the company. In addition, the company clearly defined its plan to get a major investment banker to proceed with the uplisting and then either finance its growth at […] Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals.  He is the founder and CEO of, which generates $1.6 billion in sales and employs 32,000 people. The market seems to be really lost on how to value the addition of this platform technology. CytoDyn Files Application with Nasdaq for Uplist.  Neither of these gentlemen would be willing to give up their time to deal with a company of this stature unless they saw a much bigger play. Â. Benzinga Newsdesk, Benzinga Staff Writer {{following ?  Argonne is the franchisee of Planet fitness with over 1,100 clubs nationwide. Enrollment Key Metric in Therapeutic Race Philippines EUA Relevant to CytoDyn, not Humanigen Highly Credentialed Humanigen Team Possibility of NASDAQ Uplisting for CytoDyn Over $4.00 Impact of Regulators on Stock Price Possibility of DSMC Intervention Next Week The top two COVID-19 therapeutics candidates in the approval pipeline seem to be sparring.  The company is trading at less than 10% of BioVids projected value 7months from now with a BLA Application filed. Instead of delivering a cytotoxic agent, CYDY’s PRO 140 monoclonal antibody simply blocks the CCR5 interactions preventing metastasis of the cancer indication. All rights reserved.  Stacking up to SGEN they are half the size. SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. No additional trials required.  Merck (MRK) has a small presence but there is a long history of MRK in HIV and if there is a bidding war they are sure to join in. It could extend much further in the eco system as they test this mechanism on organ transplants. With all the potential upheaval in the HIV market coming from the majors trying to knock each other off the timing couldn’t be more perfect for a deal. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented: “While we realize the regulatory review of our application to uplist to Nasdaq will take several weeks, we believe the Company is well-positioned for success. In this instance CYDY might eclipse SGEN in a 1-2 year time frame. For the past 6 months CYDY management has talked about waiting to hear from the NASDAQ regarding its up-listing application . The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. With all this preclinical work by Dr. Pestell on the CCR5 target, PRO 140 is a very convincing candidate for Phase 2b studies on cancer giving its excellent safety profile. All the current therapies in the pipeline become obsolete if this new entry inhibitor class of drugs can take root. In terms of revenue SGEN did $482 million in sales versus CYDY projections of $1.2 billion. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. This information is seen by readers ...  The first example are the preclinical results of Graft versus Host Disease (GvHD) where humanized DNA was able to survive and thrive in a foreign host.  They are the 4, largest Applebee’s franchisee with approximately 120 locations.  The company had made overtures that they would be interested in being purchased but having a billionaire investor of this caliber on the team is extremely useful (as the old saying goes it is not what you know but who you know).  Blocking the CCR5 target simply stops the cycle and takes the fangs or invasiveness of cancer out of the picture.  The current market capitalization of CYDY is only $105 million.  He is the founder and CEO of Argonne Capital Group which generates $1.6 billion in sales and employs 32,000 people. Once approved as just a combination therapy, estimates sales of $1.2 billion assuming 49,000 patients.  Each one of these companies has a vested stake and billions of dollars invested in the current standard of care called Highly Active Antiretroviral Treatment (HAART). Cytodyn Inc (CYDY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. D) CytoDyn Releases CD12 positive with the price action of shorting the News.  Seattle Genetics (SGEN) is actually an ideal case study because they have a platform technology and multiple cancer indications and show what CYDY could look like in just over a year. With all the potential upheaval in the HIV market coming from the majors trying to knock each other off the timing couldn’t be more perfect for a deal. C) Prior to readout CytoDyn receives an OWS grant purchase order and payment for product, partnership venture payment, or other investment of an amount that satisfies NASDAQ for up list. 15 juil. View more posts, WallStreetPR.com is a comprehensive publisher reporting on the pulse of the North American stock markets. Physicians reluctant to change might be slow to uptake the new combination pill for the fear of resistance justified or not.  The market has not priced in a fully functioning phase 2 cancer company with at least 4 potential indications (Breast, Colon, Prostate, MS) to get started. Â, With the recent acquisition of ProstaGene almost complete, world renowned scientist Dr Richard Pestell stepped in as the Chief Medical Officer (CMO) to oversee a massive pipeline of oncology indications that are likely to follow as metastasis is the concern in nearly every cancer indication. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency’s suggestion . Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review.  Behind them is Johnson and Johnson (JNJ) which just made news last month when it announce FDA approval of Symtuza. VANCOUVER, Washington, July 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it recently filed a comprehensive listing application package with The Nasdaq …   A video titled Cancer Metastasis Promotion by CCR5 Receptor is a must see. In April 2020, CytoDyn submitted the clinical, and the chemistry, manufacturing and controls portions of its biologics license application (BLA) to … CytoDyn Inc (CYDY) announced that Michael A. Klump joined the Board of Directors at CytoDyn. From Wall Street to Bay Street, WallStreetPR.com covers news from companies big and small with our journalists, CytoDyn Inc (CYDY) announced that Michael A. Klump, has an extensive background in financing that traces back to Argonne Capital Group LLC.  The company is the largest franchisee of IHOP with 300 restaurants and 4 partnerships. Many licensing opportunities with big pharma.  Mr. Klump has an extensive background in financing that traces back to Argonne Capital Group LLC. CytoDyn Update Reveals Q1 Sales Pipeline, Philippine EUA, NASDAQ Uplisting, & High Likelihood of Approval CytoDyn Inc. (OTCMKTS: CYDY) may have given one of its last updates as an OTC company yesterday and revealed a number of positive surprises. As we advance the evaluation of our drug, leronlimab, including the upcoming results of the COVID-19 trials, we believe a listing on Nasdaq will enhance shareholder value by providing our shareholders with improved liquidity and by giving us greater access to the capital markets, which will allow us to achieve our objective of bringing leronlimab to market.”.  CYDY is about 4-7 months from filing their complete BLA application for PRO 140. Mr. Klump has an extensive background in financing that traces back to Argonne Capital Group LLC.      Â, Alan has over 25 years of trading experience in the U.S. equity markets. In order to apply for listing on NASDAQ, a company must complete and submit to NASDAQ a listing application including specified documents and information.  The current market capitalization of CYDY is only $105 million. This means the Myeloid-derived Suppressor Cells (MDSC) known as regulatory cells that keep the CD8+ killer T-cells away would no longer be attracted to the site. All the current therapies in the pipeline become obsolete if this new entry inhibitor class of drugs can take root. Clinical manifestations in patients have ranged from non-existent to severe and fatal.  They are also the largest John Deere turf and agricultural dealership in update New York. The disparity shown is massive and as CYDY continues to do road shows and awareness the stock price should correct accordingly.  CYDY was quick to disclose that he was a “significant investor” and brought “extensive financing and mergers and acquisitions experience to the CytoDyn Board.”, The top candidate for a license/buyout deal is Gilead (GILD) with 55% of its $14 billion in annual sales dependent upon HIV. Leave a comment to automatically be entered into. Let us know so we can better customize your reading experience. For CYDY to promote a significant investor to the board and mention the mergers and acquisitions experience projects the notion that buyout or licensing discussions are indeed happening.  This billionaire investor normally deals with real estate and is not on the board of any other public companies which speaks volumes in regard to his belief in the company.  In his work he use two somewhat toxic CCR5 antagonists Mariviroc and Vicriviroc which “dramatically enhanced the cell killing mediated by DNA damaging chemotherapeutic agents.”      Â.  In February this year it rolled out a new 3 drug combination called Biktarvy. Vuzix Corporation (NASDAQ:VUZI) will be participating as a speaker in Verizon Communications Inc's upcoming event, "5G Innovation Sessions; Advancing the Mission of the DOD," at 2 pm ET on Wednesday, the company announced.In an hour-long session, Verizon will explain why 5G matters to the US Department of Defense, how it can help securely shape missions and discuss …  ProstaGene has patented discoveries for cancer metastasis therapies and a high predictive genetic test for prostate cancer. This information is seen by readers not only on TalkMarkets, but also goes out to our distribution partners which include such leading companies as Reuters, Bloomberg, Invetopedia, Benzinga, Interactive Brokers, Zacks, and many others. Once approved as just a combination therapy BioVid Market Research estimates sales of $1.2 billion assuming 49,000 patients. The timing of his appointment seems to be calculated as the company plans on courting suitors for licensing or acquisition deals with the company. The Company believes it satisfies the initial listing requirements for The Nasdaq Capital Market®. He began his career in finance working on a program trading desk specializing in over-the-counter stocks.  They are also the largest John Deere turf and agricultural dealership in update New York. About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. CytoDyn Reports Filing Of application For Nasdaq Uplist. The disparity shown is massive and as CYDY continues to do road shows and awareness the stock price should correct accordingly.  They are the 4th largest Applebee’s franchisee with approximately 120 locations. If there is a label expansion to monotherapy that number rises to $3.8 billion.  While at Jefferson College, he publish many peer-reviewed publication on the CCR5 receptor and its implication to cancer. If there is a label expansion to monotherapy that number rises to $3.8 billion. With 7 indications of cancer they are roughly double the size of CYDY. (https://plus.google.com/103338576216002376250).  SGEN is partnered with Takeda, ABBV, GSK, and Genmab.  CYDY was quick to disclose that he was a “significant investor” and brought “extensive financing and mergers and acquisitions experience to the CytoDyn Board.”, New Acquisition Leads to Pipeline Expansion. CytoDyn Files Application with Nasdaq for Uplist .  The whole industry is only one drug approval away from billions in research going down the drain.  This billionaire investor normally deals with real estate and is not on the board of any other public companies which speaks volumes in regard to his belief in the company. The site is an innovator in business news, videos and insightful market content that generates hundreds of articles weekly. Likely Suitors + Growing Friction in Market = Speculation on Entry Inhibitor, The top candidate for a license/buyout deal is Gilead (GILD) with 55% of its $14 billion in annual sales dependent upon HIV.